Althera Pharmaceuticals Inc.

Despite the paucity of enforcement letters objecting to prescription drug promotions, the US Food and Drug Administration has shown concern about one aspect of advertisements: efficacy claims that are

The US Food and Drug Administration’s Office of Prescription Drug Promotion has not cited a company for advertising violations since last June so its untitled letter to Xeris Biopharma Holdings, Inc.

The stream of research projects from the US Food and Drug Administration’s Office of Prescription Drug Promotion has slowed with only three studies being initiated in each of the last two years, half

Gilead Sciences, Inc. turned to the National Advertising Division rather than the US Food and Drug Administration when it sought action against ViiV Healthcare ’s Dovato HIV drug advertising claims.